Oculus Innovative Sciences Announces Fiscal Third Quarter 2016 Financial Results and Conference Call
January 21, 2016 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Jan. 21, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (tradable warrants OCLSW) today announced that the financial results for its fiscal third quarter...
Oculus Innovative Sciences Receives European CE Mark for New MucoClyns™ for First Responders
January 14, 2016 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), warrants OCLSW, a specialty pharmaceutical company that develops and markets solutions for...
Oculus Innovative Sciences Receives FDA Clearance for Microcyn®-Based SebDerm Gel
December 17, 2015 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Dec. 17, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the...
Oculus Innovative Sciences Announces Fiscal Second Quarter 2016 Financial Results and Conference Call
October 22, 2015 06:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Oct. 22, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), tradable warrants (NASDAQ:OCLSW) today announced that the financial results for its fiscal...
Oculus Innovative Sciences Introduces MicrocynAH(R) Next-Generation Dermatology Products With Dimethicone for Animals
September 24, 2015 06:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (tradable warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions...
Oculus Innovative Sciences Announces Preliminary Results for Its 2015 Annual Meeting of Stockholders
September 11, 2015 18:30 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Sept. 11, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), tradeable warrants (NASDAQ:OCLSW) today announced that the four proposals presented in its annual...
Oculus Innovative Sciences Announces Introduction of Alevicyn SG Antipruritic Spray Gel for Relief of Pain and Itch in Atopic Dermatitis
August 19, 2015 06:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Aug. 19, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), a specialty pharmaceutical company that develops and markets solutions for the treatment of...
Oculus Innovative Sciences Reports Financial Results for the First Quarter of Fiscal Year 2016
July 30, 2015 16:05 ET
|
Sonoma Pharmaceuticals, Inc.
U.S. dermatology and Latin American sales drive 37% product revenue growth
FDA 510k clearance for treatment of atopic dermatitis with a unique "no touch" spray gel
Cash as of June 30,...
Oculus Innovative Sciences Announces Fiscal First Quarter 2016 Financial Results and Conference Call
July 16, 2015 06:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., July 16, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced that the financial results for its fiscal first quarter 2016, ended June 30, 2015,...
Oculus Innovative Sciences Receives New U.S. Patent for Microcyn(R) Technology in Treatment of Atopic Dermatitis
July 08, 2015 06:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., July 8, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a specialty pharmaceutical company that develops and markets solutions for the treatment of...